ERBB2 and breast cancer: Beyond confirming the notion that the occurrence of a basal-HER2+ phenotype can delineate a subgroup of intrinsically aggressive cHER2+ BC, a recent study by our group was the first to reveal that basal-HER2+ patients might not benefit from the addition of trastuzumab on top of chemotherapy [22].